Slides on Key Decisions in HIV Care: Treating HIV/HCV Coinfection

Learn the data and recommendations for treating HIV and HCV in patients who are coinfected, including considerations for HCV treatment as prevention and the impact of HCV treatment on the HIV care cascade.
Mark S. Sulkowski, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 908 KB
Released: January 26, 2022

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Christine Katlama discusses minimizing ART exposure with dual-therapy and intermittent dosing strategies, from Clinical Care Options (CCO)

person default Christine Katlama, MD Released: January 4, 2023

Dr Melissa Badowski shares key data about the causes of and recommendations for managing ART failure, from Clinical Care Options (CCO)

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Pharmacists: 0.5 contact hours (0.05 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Expert HIV faculty analyze new data from AIDS 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Princy N. Kumar, MD, FIDSA, MACP person default Mary W. Montgomery, MD David A. Wohl, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Dr Babafemi Taiwo discusses the emergence of lenacapavir for the treatment of multidrug-resistant HIV, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: December 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings